Curaleaf International has announced the successful license of its range of cannabis-based medicines as extract under the name Adven, in Malta.
Curaleaf’s product range is being manufactured to meet the growing demand for high quality medical cannabis products across Europe.
As Europe’s largest vertically integrated cannabis company, this development builds on Curaleaf International being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient in Italy.
Curaleaf International CEO, Antonio Costanzo, commented: “We are very proud of this achievement.
Read more: Curaleaf International on the growth of the European cannabis market
“Thanks to Curaleaf International’s regulatory expertise in pharmaceuticals we have obtained registration of a full line of medicinal products to support doctors, pharmacists and patients’ demands for high quality cannabis products going forward.
“We believe this will open a new era of opportunity for licensed cannabis-based medicines in the Maltese market.
“This news, in addition to our recent registration in Italy, is very promising momentum for Curaleaf International as we continue to witness growing demand for our products across the growing European market.”
The products are already being prescribed to a growing number of patients in the UK and Germany.
Read more: Curaleaf is championing social impact in the cannabis industry
The licensed cannabis-based medicine range incorporates a variety of different strengths and THC/CBD formulations in oil format, which will address a wide range of specialist requirements, all sourced from Europe, from plant to manufacture and are EU-GMP certified.
Curaleaf CSO, Barbara Pacchetti, said: “Curaleaf International is committed to advancing the industry’s understanding of the medical potential of cannabis through licensed cannabis-based medicines.
“We anticipate a new era to place cannabis-based medicine in therapeutical disease protocols alongside conventional drugs.
“Our pioneering scientific research and clinical programmes are designed to provide more clinical data to underpin the growing medical cannabis market. Our aim is to continue to generate evidence regarding the potential therapeutic benefits of medical cannabis for patients and clinicians.”
[activecampaign form=31]
